Retatrutide: A Triple Agonist in Phase 3

The short version

Retatrutide (also catalogued as LY3437943) is an investigational synthetic peptide 39 amino acids long that activates three receptors at once: the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The GLP-1 and GIP arms suppress appetite and boost glucose-dependent insulin secretion; the glucagon arm adds energy expenditure and fat mobilization on top of that ^[1]. The triple combination produced mean body-weight reductions of approximately 24.2% at the highest dose over 48 weeks in a Phase 2 obesity trial — a figure larger than earlier single and dual incretin trials ^[4].

The honest constraint is timing. Retatrutide has not been approved by the FDA or any regulator. All efficacy figures come from Phase 1 and Phase 2 trials; pivotal Phase 3 trials (the TRIUMPH series) are ongoing with results not yet available as of mid-2026 ^[1]. Gray-market material sold as retatrutide is unregulated and of unverified identity and purity. This page reports what the published studies show; it lists no human dose and gives no advice.

What it is

Retatrutide is a synthetic 39-amino-acid peptide built on a GIP-based backbone. It is acylated with a C20 fatty-diacid moiety — the same albumin-binding engineering used in other long-acting incretin peptides — which confers high affinity for plasma albumin and extends its half-life to approximately six days, enabling once-weekly subcutaneous dosing ^[6]. Its molecular formula is C221H342N46O68 (free acid).

It engages three receptors. Cryo-EM structural work resolved its simultaneous binding to GLP-1R, GIPR, and GCGR (the glucagon receptor), confirming triple agonism in a single molecule ^[2]. Relative potency measured by cAMP assays: approximately 8.9× native GIP at GIPR, 0.4× native GLP-1 at GLP-1R, and 0.3× native glucagon at GCGR ^[2]. The glucagon arm is deliberately attenuated to limit hepatic glucose output while preserving energy expenditure.

How it works

The mechanism is additive across three receptor pathways. At the GLP-1 receptor, retatrutide slows gastric emptying, suppresses appetite through central and peripheral signaling, and augments glucose-dependent insulin secretion. At the GIP receptor, it further potentiates insulin release and, through GIP's effect on adipose tissue, promotes lipid storage redistribution. At the glucagon receptor, it drives hepatic energy expenditure and lipid oxidation — a thermogenic lever absent from single or dual GLP-1 agents ^[1].

A metabolomics analysis of Phase 2 participants confirmed that higher retatrutide doses reduced triglycerides and branched-chain amino acids (a biomarker cluster associated with insulin resistance and cardiovascular risk), and showed that changes in the fatty acid oxidation cluster mediated roughly 23% of the observed weight reduction in participants without type 2 diabetes ^[7]. In plain terms: the glucagon arm appears to shift energy metabolism toward fat burning, not just appetite suppression.

What the research shows

Phase 1b first-in-human (2022). In 72 adults with type 2 diabetes, a 12-week multiple-ascending-dose study established the approximately 6-day half-life and once-weekly dosing schedule. The highest-dose group lost a placebo-adjusted mean of 8.96 kg over 12 weeks. Treatment-emergent adverse events were mostly gastrointestinal (63% of participants); the safety profile was considered acceptable for advancement ^[6].

Phase 2 obesity trial — 48 weeks (2023). In 338 adults with obesity (BMI ≥30, or ≥27 with a comorbidity), once-weekly retatrutide produced mean body-weight changes of −24.2% (12 mg) versus −2.1% with placebo at 48 weeks. GI adverse events were dose-related and mostly mild to moderate. A dose-dependent increase in resting heart rate peaked at week 24 ^[4].

Phase 2 type 2 diabetes trial — 36 weeks (2023). In 281 adults with type 2 diabetes, the 12 mg dose reduced HbA1c by −2.02 percentage points (versus −0.01 for placebo at 24 weeks) and body weight by −16.94% (versus −3.00% for placebo at 36 weeks). No severe hypoglycemia or deaths were recorded ^[5].

MASLD substudy — 48 weeks (2024). In 98 participants with obesity/overweight and metabolic dysfunction-associated steatotic liver disease, retatrutide 12 mg reduced liver fat by −82.4% at 24 weeks by MRI-PDFF; 86% reached normal liver fat (<5%). Reductions were sustained at 48 weeks (−86.0%) ^[3].

Structural biology (2024). Cryo-EM structures resolved retatrutide simultaneously bound to all three receptors at 2.68–3.26 Å resolution, confirming the molecular basis of triple agonism and characterizing the conformational differences at each receptor interface ^[2].

Metabolomics post-hoc (2026). Analysis of Phase 2 RCT plasma samples from 282 obesity and 213 T2D participants quantified triglyceride and insulin-resistance-biomarker reductions and the fatty acid oxidation mediation of weight response ^[7].

Reported effects, cautions & safety

Reported effects from research-use communities (anecdotal field reports, not clinical data — listed separately from trial evidence):

Community members using retatrutide in research contexts frequently report strong appetite suppression — often described as food noise going quiet — rapid and pronounced weight reduction, a thermogenic warmth attributed to the glucagon arm, elevated resting heart rate (consistent with trial data), nausea peaking early and diminishing with time, sulfur burps, fatigue in initial weeks, constipation, and occasional injection site itching. A subset notes mood uplift and reports concern about lean-mass preservation during rapid loss. These are unverified self-reports with no confirmed doses; individual variation is high. Anecdotal field reports, not clinical evidence.

Safety cautions from the published literature:

• Unapproved and unregulated supply. Retatrutide has no FDA or regulatory approval as of mid-2026. Gray-market material cannot be verified for identity, purity, sterility, or concentration. The FDA issued warning letters to retatrutide vendors in 2025 citing FD&C Act violations ^[4][1].
• GI adverse events. Nausea, vomiting, diarrhea, and constipation were the most common adverse effects in trials, were dose-related, and drove the 18% discontinuation rate at the highest dose. Without medically supervised dose escalation, risk of severe GI events and dehydration is higher ^[4][5][6].
• Heart rate increase. Phase 2 data show dose-dependent mean heart-rate elevations of approximately 5–7 bpm, peaking around week 24, attributed to glucagon-receptor-mediated cardiac chronotropy ^[4][6]. Unmonitored use in individuals with pre-existing arrhythmia or cardiovascular disease carries unknown risk.
• Lean-mass reduction. Body-composition data confirm retatrutide reduces lean mass alongside fat mass. The ratio is more favorable than bariatric benchmarks, but absolute lean loss is clinically meaningful — particularly without adequate protein intake and resistance exercise ^[7].
• Drug interaction: insulin and sulfonylureas. Retatrutide's GLP-1 and GIP agonism augments insulin secretion; combined with exogenous insulin or sulfonylureas, hypoglycemia risk increases materially. Phase 2 diabetic participants required insulin dose de-escalation ^[5][6].
• Long-term unknowns. No outcome-trial results exist yet. Cardiovascular, renal, and durability-after-discontinuation data are still pending from ongoing TRIUMPH, NCT06383390, and kidney-outcome trials ^[1][4].

Where it fits in metabolic research

Retatrutide is the lead compound on this desk because it represents the current frontier of incretin pharmacology: triple agonism, Phase 3 data imminent, and the largest weight-reduction signal yet reported from a controlled trial ^[1][4]. Where tirzepatide is fully approved with multiple Phase 3 programs complete, retatrutide's profile is still being defined by ongoing trials. The glucagon-receptor arm is the structural difference — it adds the energy-expenditure component that neither tirzepatide nor single GLP-1 agents carry. Whether that translates to meaningfully different real-world outcomes will be answered by TRIUMPH. See the comparison page for how the two line up.